Innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models applied to vamorolone drug development
Clinical Trials
Vamorolone is in clinical testing for Duchenne Muscular Dystrophy (NCT05185622) and Becker Muscular Dystrophy (NCT05166109).
Learn More >
About vamorolone
Vamorolone is the first therapy for Duchenne muscular dystrophy receiving approval in both EU (EMA) and US (FDA).
Research
Vamorolone shows efficacy in Duchenne Muscular Dystrophy and safety advantages over prednisone (Guglieri et al. 2022).
Data from international public/private partnership leads to the first therapy for Duchenne muscular dystrophy approved by both EMA and FDA.
Rockville, MD, USA, December 22, 2023
The EMA approved AGAMREE (vamorolone) for Duchenne muscular dystrophy (DMD), ages 4 years and older on 18 December 2023. The US FDA previously approved AGAMREE for DMD (26 October 2023). This makes AGAMREE the first